- Home
- DTE vs ZTS Comparison
DTE vs ZTS Comparison
Compare DTE & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTE | ZTS |
|---|---|---|
| Founded | 1903 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 32.5B |
| IPO Year | 2001 | 2012 |
Fundamental Metrics
Financial Performance| Metric | DTE | ZTS |
|---|---|---|
| Price | $122.89 | $71.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $153.31 | ★ $154.18 |
| AVG Volume (30 Days) | 1.4M | ★ 3.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.17% | 1.86% |
| EPS Growth | 3.84 | ★ 10.05 |
| EPS | 1.19 | ★ 3.08 |
| Revenue | ★ $12,607,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | N/A | $5.63 |
| Revenue Next Year | $3.36 | $4.77 |
| P/E Ratio | $105.39 | ★ $23.67 |
| Revenue Growth | ★ 18.60 | 2.28 |
| 52 Week Low | $125.13 | $70.26 |
| 52 Week High | $155.75 | $148.79 |
Technical Indicators
Market Signals| Indicator | DTE | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.70 |
| Support Level | N/A | $71.32 |
| Resistance Level | N/A | $78.20 |
| Average True Range (ATR) | 0.00 | 1.49 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 0.00 | 32.24 |
Price Performance
Historical ComparisonAbout DTE DTE Energy Company
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.